drugset / Trial / NCT00677118

Summary

The purpose of this study is to compare concurrent chemoradiotherapy plus adjuvant chemotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced NPC, in order to evaluate the value of adjuvant chemotherapy in nasopharyngeal carcinoma (NPC) patients.

Timeline

Start
2006-06
Primary completion
2015-03
Completion
2015-03

Outcome

Missed primary endpoint

paper Adjuvant cisplatin and fluorouracil chemotherapy did not significantly improve failure-free survival after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma. PMID 22154591 ↗

paper hazard ratio 0.88, 95% confidence interval 0.64-1.22; p = 0.45 PMID 28235726 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 40 mg/m2 —
Subject Cisplatin Other / unclassified 80 mg/m2 —
Subject fluorouracil Small molecule 800 mg/m2 —